Download full-text PDF |
Source |
---|
BMC Geriatr
January 2025
James P. Wilmot Cancer Institute, Rochester, New York, USA.
Background: Older adults with cancer are vulnerable to declines in muscle performance (e.g., strength, speed, duration of muscular contraction), which are associated with worse cancer-related outcomes.
View Article and Find Full Text PDFMicrob Ecol
January 2025
Department of Biology, University of Rome Tor Vergata, 00133, Rome, Italy.
Posidonia oceanica retains a large amount of carbon within its belowground recalcitrant structure, the 'matte,' which is characterized by low oxygen availability and biodegradation. Fungi may play a pivotal role in carbon sequestration within the matte, even if little/no information is available. To fill this gap, we profiled fungal communities from the upper and lower layers of alive and dead matte, by using an ITS2-5.
View Article and Find Full Text PDFInt J Oral Maxillofac Surg
January 2025
Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Chulalongkorn University, Bangkok, Thailand. Electronic address:
The aim of this study was to determine the effects of mandibular setback surgery exceeding 5 mm on upper airway and sleep quality in skeletal Class III patients, with comparisons to Class I controls. Sixteen individuals per group were selected based on their ANB angle and surgical need. 2D and 3D airway analyses were conducted.
View Article and Find Full Text PDFJ Allergy Clin Immunol
January 2025
Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Background: Determining why some upper respiratory illnesses provoke asthma exacerbations remains an unmet need.
Objective: To identify transcriptome-wide gene expression changes associated with colds that progress to exacerbation.
Methods: 208 urban children (6-17 years) with exacerbation-prone asthma were prospectively monitored for up to two cold illnesses.
Lancet Gastroenterol Hepatol
January 2025
The Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition, The Eisenberg R&D Authority, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel. Electronic address:
Background: Infliximab and adalimumab are the only biologics thus far approved for paediatric patients with inflammatory bowel disease (IBD), so other biologics, such as vedolizumab, are prescribed off-label. Despite its frequent use, prospective data for vedolizumab treatment in children are available only for short-term induction outcomes. We aimed to evaluate the long-term efficacy and safety of maintenance therapy with vedolizumab in paediatric patients with IBD.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!